Patents by Inventor Hans Lindner

Hans Lindner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10307459
    Abstract: Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 4, 2019
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Publication number: 20180280469
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: January 26, 2018
    Publication date: October 4, 2018
    Applicant: Ferring B.V.
    Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
  • Patent number: 9919025
    Abstract: Described herein are orodispersible pharmaceutical dosage forms of desmopressin comprising desmopressin free base or a pharmaceutically acceptable salt thereof, and one or more carriers, wherein at least one carrier is hydrolyzed gelatin in an open matrix network structure. Also described are methods of making and using such desmopressin orodispersible pharmaceutical dosage forms.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: March 20, 2018
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Publication number: 20170112895
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: October 25, 2016
    Publication date: April 27, 2017
    Applicant: Ferring B.V.
    Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
  • Patent number: 9504647
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: November 29, 2016
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Publication number: 20160175246
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: November 20, 2015
    Publication date: June 23, 2016
    Applicant: Ferring B.V.
    Inventors: Anders NILSSON, Hans LINDNER, Jørgen WITTENDORFF
  • Patent number: 9220747
    Abstract: Described are orodispersible solid dosage forms of desmopressin or a pharmaceutically acceptable salt thereof useful for treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus. The dosage forms disintegrate in the mouth within 10 seconds and provide good desmopressin bioavailability.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: December 29, 2015
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jçrgen Wittendorff
  • Publication number: 20150150938
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: July 9, 2014
    Publication date: June 4, 2015
    Applicant: Ferring BV
    Inventors: Anders Nilsson, Hans LINDNER, Jørgen WITTENDORFF
  • Patent number: 8802624
    Abstract: Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 ?g.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: August 12, 2014
    Assignee: Ferring B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Publication number: 20130296423
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Patent number: 8501723
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 6, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
  • Publication number: 20120071538
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: May 18, 2011
    Publication date: March 22, 2012
    Inventors: Anders Nilsson, Hans Lindner, JØRGEN Wittendorff
  • Patent number: 7947654
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: May 24, 2011
    Assignee: Ferring B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Patent number: 7737088
    Abstract: The present invention relates to arrays of biochemical and/or biofunctional elements such as nucleic acids (oligonucleotides, for example) or other biomolecules on a carrier surface and methods of producing such arrays using photoactivation of predetermined areas for synthesis using an illumination matrix that is computer-controlled to generate an exposure pattern. This exposure pattern can be adjusted and monitored by computer using a light sensor matrix, for example a CCD matrix, to allow precise, controlled illumination of specific regions and therefore attachment of array building blocks to those specific regions. The methods and compositions of the invention permit spatially resolved photochemical synthesis of polymer probes on a carrier.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: June 15, 2010
    Assignee: Febit Holding GmbH
    Inventors: Cord F. Stähler, Peer F. Stähler, Manfred Müller, Fritz Stähler, Hans Lindner
  • Publication number: 20100130606
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 27, 2010
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20090318665
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Application
    Filed: June 18, 2009
    Publication date: December 24, 2009
    Inventors: Anders Nilsson, Hans Lindner, Jorgen Wittendorff
  • Patent number: 7560429
    Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: July 14, 2009
    Assignee: Ferring B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Publication number: 20090117159
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: December 23, 2008
    Publication date: May 7, 2009
    Applicant: SCHWARZ PHARMA AG
    Inventors: Hans-Jurgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20080214412
    Abstract: The present invention relates to arrays of biochemical and/or biofunctional elements such as nucleic acids (oligonucleotides, for example) or other biomolecules on a carrier surface and methods of producing such arrays using photoactivation of predetermined areas for synthesis using an illumination matrix that is computer-controlled to generate an exposure pattern. This exposure pattern can be adjusted and monitored by computer using a light sensor matrix, for example a CCD matrix, to allow precise, controlled illumination of specific regions and therefore attachment of array building blocks to those specific regions. The methods and compositions of the invention permit spatially resolved photochemical synthesis of polymer probes on a carrier.
    Type: Application
    Filed: January 9, 2008
    Publication date: September 4, 2008
    Inventors: Cord F. Stahler, Peer F. Stahler, Manfred Muller, Fritz Stahler, Hans Lindner
  • Publication number: 20080138421
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: June 7, 2007
    Publication date: June 12, 2008
    Inventors: Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner